"This is the site for Loyola University Health Sciences Campus, NOT the Loyola University Medical Center."

During the past decade, Loyola University Chicago conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 19 clinical trials were completed, i.e. on average, 126.7% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 12 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Loyola University Chicago" #1 sponsor was "Biosense Webster, Inc." with 3 trials, followed by "Loyola University" with 3 trials sponsored, "Celgene" with 2 trials sponsored, "Abbott Medical Devices" with 1 trials sponsored and "AiCuris Anti-infective Cures AG" with 1 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Loyola University Chicago" #1 collaborator was "Center for International Blood and Marrow Transplant Research" with 1 trials as a collaborator, "Clinipace Worldwide" with 1 trials as a collaborator, "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "Emissary International LLC" with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Loyola University Chicago" are "Coronary Artery Disease" (2 trials), "Diabetes" (2 trials), "Lymphoma" (2 trials), "Obesity" (2 trials) and "ADPKD" (1 trials). Many other conditions were trialed in "Loyola University Chicago" in a lesser frequency.

Most popular intervention types in "Loyola University Chicago" are "Drug" (18 trials), "Device" (9 trials), "Biological" (4 trials), "Behavioral" (3 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Oral Azacitidine" (2 trials), "THERMOCOOL® SMARTTOUCH™ Catheter" (2 trials), "120 mg AIC246" (1 trials) and "240 mg AIC246" (1 trials). Other intervention names were less common.

The vast majority of trials in "Loyola University Chicago" are 31 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Loyola University Chicago". undefined are not yet recruiting, 2 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Loyola University Chicago, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Loyola University Chicago, 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 5 trials that are defined as “Not Applicable".